Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR440340 proof-of-concept study in moderate-to-severe COPD
2017-003290-34Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing SAR440340 with Placebo (2 arms). Primary endpoint: Annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease. Started Jul 2018; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-003290-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003290-34.